Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 287

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 287
---
538 Ordinary Shares following the consummation of this offering.

On December 1, 2024, we
entered into the December 2024 Loan Agreement with our Chief Executive Officer, according to which accrued payroll salary owed to him
in the aggregate amount of $117,000 plus VAT was converted into a loan. The loan amount bears interest at an 8% annual rate, and is due
upon the earlier of the consummation of this offering or March 31, 2025. In addition, upon maturity, the Company will pay to our Chief
Executive Officer an aggregate risk premium equal to 30% of the loan amount (or approximately $35,100 plus VAT). If a registration statement
for an initial public offering is made effective no later than March 31, 2025, then the maturity date will be extended to June 30, 2025.
In addition, pursuant to the December 2024 Loan Agreement, upon the consummation of this offering the Company will issue warrants, or
the CEO Loan Warrants, exercisable for a period of three years from the date of the issuance, to purchase such number of Ordinary Shares
equal to two times the respective loan amount divided by 75% of the lowest price per Ordinary Share during the first five trading days
following the consummation of this offering, at an exercise price equal to 75% of the lowest price per Ordinary Share during the first
five trading days following the consummation of this offering. The outstanding debt will become immediately due and payable upon an event
of default (as defined in the December 2024 Loan Agreement), which shall be deemed to have occurred upon certain circumstances as detailed
in the December 2024 Loan Agreement. On March 31, 2025, we and our Chief Executive Officer entered an amendment to the December 2024
Loan Agreement to extend the maturity date until the earlier of August 31, 2025, or the consummation of an IPO. On July 1, 2025, we entered
into an amendment to the December 2024 Loan Agreement such that our Chief Executive Officer shall be granted warrants to purchase up
to 55,224 Ordinary Shares following the consummation of this public offering.

In April 2025, we entered
into bridge loan agreements, or the 2025 Loan Agreements, pursuant to which we obtained a bridge loans in the aggregate amount of $200,000
from certain lenders, including certain related parties